🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
To compare the therapeutic effect of vinorelbine used alone or combined wit...
Status
Unknown
Location
Multiple Locations
Start Date
2019-06-24
Trial ID
NCT03932526
Treatments Being Tested
Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a ...
Status
Terminated
Location
Multiple Locations
Start Date
2002-07
Trial ID
NCT00169104
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of anlotin...
Status
Unknown
Location
Henan Cancer Hospital
Start Date
2022-03-22
Trial ID
NCT05296577
Treatments Being Tested
The investigators performed a multi-center, randomized, controlled, double-...
Status
Completed
Location
ShanghaiUTCM
Start Date
2011-11
Trial ID
NCT01441752
The objective of the present study is to estimate the overall survival of p...
Status
Completed
Location
Centre Pierre et Marie Curie (CPMC)
Start Date
2015-11
Trial ID
NCT03413579
Treatments Being Tested
The main object of this trial is to offer treatment of recombinant endostat...
Status
Completed
Location
Bengbu medical college affiliated hospital
Start Date
2011-11-10
Trial ID
NCT03117335
To determine whether tariquidar + first-line single agent vinorelbine chemo...
Status
Terminated
Location
Multiple Locations
Start Date
2002-06
Trial ID
NCT00042315
Treatments Being Tested
The main objective of the trial is to document the efficacy of NGR-hTNF adm...
Status
Completed
Location
Wilshire Oncology Medical Group
Start Date
2010-04-12
Trial ID
NCT01098266
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of QL1706 ...
Status
Recruiting
Location
Shanghai Pulmonary Hospital, Shanghai. China
Start Date
2022-12-08
Trial ID
NCT05487391
Treatments Being Tested
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab,...
Status
Unknown
Location
Jong-Mu Sun
Start Date
2018-11-01
Trial ID
NCT03656094
Treatments Being Tested